Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
- PMID: 36580143
- PMCID: PMC9941271
- DOI: 10.1007/s00228-022-03442-8
Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
Abstract
Objectives: We investigated the efficacy of intensive rosuvastatin therapy plus 7-day dual antiplatelet therapy (DAPT) in reducing stroke recurrence for patients with acute ischemic stroke (AIS) and compared subgroups of patients.
Methods: We enrolled patients with AIS whose time of onset to medication was ≤ 72 h, and the baseline scores of NIHSS (bNIHSS) were 0-10. The patients received intensive rosuvastatin therapy plus 7-day DAPT with aspirin and clopidogrel (study group) or rosuvastatin plus single antiplatelet therapy (SAPT, control group). The primary outcomes were recurrence of ischemic stroke, bleeding, statin-induced liver injury, and statin-associated myopathy (SAM) within 90 days. We also performed a subgroup analysis to assess the heterogeneity of the two therapy regimens in reducing recurrent stroke.
Results: Recurrent stroke occurred in 10 patients in the study group and 42 patients in the control group (hazard ratio [HR], 0.373, 95% confidence interval [CI], 0.178-0.780; P = 0.009). Bleeding events occurred in 9 patients in the study group and 14 patients in the control group (HR, 1.019; 95%CI, 0.441-2.353; P = 0.966). Statin-induced liver injury and SAM were not recorded. Intensive rosuvastatin plus 7-day DAPT was generally effective in reducing the risk of recurrent stroke, except in the subgroup with bNIHSS ≤ 2. The therapy was particularly efficient in the elderly, male, high-bNIHSS, and hypertension, diabetes, and hyperlipidemia subgroups, with P < 0.02.
Conclusions: Without increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.
Clinical trial registration: China Clinical Trial Registration Center (ChiCTR1800017809).
Keywords: Dual antiplatelet therapy; Intensive rosuvastatin; Recurrent ischemic stroke; Subgroup analysis.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
A comparison of safety and efficacy between long-term DAPT and intensive statins combined with short-term DAPT for acute ischemic stroke.Eur J Med Res. 2023 Apr 21;28(1):154. doi: 10.1186/s40001-023-01115-5. Eur J Med Res. 2023. PMID: 37081514 Free PMC article.
-
Safety and efficacy of short-term dual antiplatelet therapy combined with intensive rosuvastatin in acute ischemic stroke.Clinics (Sao Paulo). 2023 Feb 2;78:100171. doi: 10.1016/j.clinsp.2023.100171. eCollection 2023. Clinics (Sao Paulo). 2023. PMID: 36738644 Free PMC article.
-
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclerosis (INSPIRES).Stroke Vasc Neurol. 2023 Jun;8(3):249-258. doi: 10.1136/svn-2022-002084. Epub 2023 Jan 27. Stroke Vasc Neurol. 2023. PMID: 36707080 Free PMC article. Clinical Trial.
-
Efficacy and safety of dual versus mono antiplatelet therapy in patients with stroke or transient ischemic attack: An updated meta-analysis of 18 randomized controlled trials.Pharmazie. 2020 Oct 1;75(10):516-523. doi: 10.1691/ph.2020.0683. Pharmazie. 2020. PMID: 33305729 Review.
-
Efficacy and safety of short-term dual- versus mono-antiplatelet therapy in patients with ischemic stroke or TIA: a meta-analysis of 10 randomized controlled trials.J Neurol. 2016 Nov;263(11):2247-2259. doi: 10.1007/s00415-016-8260-7. Epub 2016 Aug 19. J Neurol. 2016. PMID: 27541045 Review.
References
-
- Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol. 2009;54(6):558–565. doi: 10.1016/j.jacc.2009.05.028. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical